Back to search
FDAFDA · Food and drugs·Recall number D-0218-2017

Bupivacaine Hydrochloride Inj., USP (2.5 mg/mL) 0.25%, packaged in 30 mL Single-dose Preservative-Free vials, Rx Only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1159-02

Published December 28, 2016 · Recall initiated: August 4, 2016

Summary

FDA records drug Class I recall D-0218-2017, published December 28, 2016 and initiated August 4, 2016. Recalling firm: Hospira Inc., A Pfizer Company; Status: Ongoing; Reported quantity: 143,250 vials; Lot: Lot # 59064DK, Exp. 11/17. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of particulate matter: Confirmed customer report for the presence of particulate matter within a single vial.

What to do

Voluntary: Firm initiated · Letter

Get an email if BUPIVACAINE HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
BUPIVACAINE HYDROCHLORIDE
Manufacturer
Hospira Inc., A Pfizer Company
Distributor
Nationwide
Lot
Lot # 59064DK, Exp. 11/17
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Bupivacaine Hydrochloride Inj., USP (2.5 mg/mL) 0.25%, packaged in 30 mL Single-dose Preservative-Free vials, Rx Only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1159-02 recalled?

Yes. FDA published recall D-0218-2017 on December 28, 2016. Reported hazard: Presence of particulate matter: Confirmed customer report for the presence of particulate matter within a single vial.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: BUPIVACAINE HYDROCHLORIDE.